Breast Cancer
CE/CME accredited
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
Videos
Learning Objectives & Overview
Claim Credit
Toolkit
Notes
This activity is CE/CME accredited
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim Credit
You may also be interested in...
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
GO TO HUB
CONFERENCE HUB
Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial
GO TO HUB
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Meeting 2019?
LAUNCH ACTIVITY
JOURNALS
Chemotherapy Options for Metastatic HER2-Negative Breast Cancer after Prior Exposure to Anthracyclines and Taxanes
GO TO ARTICLE
JOURNALS
Practical Considerations in Bone Metastases in Breast Cancer
GO TO ARTICLE
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Claim Credit
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
You may also be interested in...
JOURNALS
Foreword – touchREVIEWS in Oncology & Haematology , Volume 20, Issue 1, 2024
GO TO ARTICLE
CONFERENCE HUB
Oleg Gluz, ESMO 2022: Analysis of ADAPT and ADAPTcycle trials – Endocrine therapy response in breast cancer
GO TO HUB
CONFERENCE HUB
Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer
GO TO HUB
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Meeting 2019?
LAUNCH ACTIVITY
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?
LAUNCH ACTIVITY
JOURNALS
Foreword – Oncology & Hematology Review (US), 2013;9(1):5
GO TO ARTICLE
Copied to clipboard!
accredited arrow-down-editable arrow-down arrow_left arrow-right-blue arrow-right-dark-blue arrow-right-green arrow-right-grey arrow-right-orange arrow-right-white arrow-right-blue arrow-up-orange avatar calendar chevron-down Clicky Media Logo consultant-pathologist-nurse consultant-pathologist cross cross download email exclaimation feedback filter graph-arrow interviews link mdt_icon more_dots nurse-consultant padlock patient-advocate-pathologist patient-consultant patient person pharmacist-nurse play_button play-colour-tmc play-colour Asset 1 podcast printer scenery search share single-doctor social_facebook social_googleplus social_instagram social_linkedin_alt social_linkedin_alt social_pinterest social_youtube shape-star (1) tick-blue tick-orange tick-red tick-white tick time transcript up-arrow webinar
Department Location NEW TMM Corporate Services Icons-07 NEW TMM Corporate Services Icons-08 NEW TMM Corporate Services Icons-09 NEW TMM Corporate Services Icons-10 NEW TMM Corporate Services Icons-11 NEW TMM Corporate Services Icons-12 Salary £ TMM-Corp-Site-Icons-01 TMM-Corp-Site-Icons-02 TMM-Corp-Site-Icons-03 TMM-Corp-Site-Icons-04 TMM-Corp-Site-Icons-05 TMM-Corp-Site-Icons-06 TMM-Corp-Site-Icons-07 TMM-Corp-Site-Icons-08 TMM-Corp-Site-Icons-09 TMM-Corp-Site-Icons-10 TMM-Corp-Site-Icons-11 TMM-Corp-Site-Icons-12 TMM-Corp-Site-Icons-13 TMM-Corp-Site-Icons-14 TMM-Corp-Site-Icons-15 TMM-Corp-Site-Icons-16 TMM-Corp-Site-Icons-17 TMM-Corp-Site-Icons-18 TMM-Corp-Site-Icons-19 TMM-Corp-Site-Icons-20 TMM-Corp-Site-Icons-21 TMM-Corp-Site-Icons-22 TMM-Corp-Site-Icons-23 TMM-Corp-Site-Icons-24 TMM-Corp-Site-Icons-25 TMM-Corp-Site-Icons-26 TMM-Corp-Site-Icons-27 TMM-Corp-Site-Icons-28 TMM-Corp-Site-Icons-29 TMM-Corp-Site-Icons-30 TMM-Corp-Site-Icons-31 TMM-Corp-Site-Icons-32 TMM-Corp-Site-Icons-33 TMM-Corp-Site-Icons-34 TMM-Corp-Site-Icons-35 TMM-Corp-Site-Icons-36 TMM-Corp-Site-Icons-37 TMM-Corp-Site-Icons-38 TMM-Corp-Site-Icons-39 TMM-Corp-Site-Icons-40 TMM-Corp-Site-Icons-41 TMM-Corp-Site-Icons-42 TMM-Corp-Site-Icons-43 TMM-Corp-Site-Icons-44 TMM-Corp-Site-Icons-45 TMM-Corp-Site-Icons-46 TMM-Corp-Site-Icons-47 TMM-Corp-Site-Icons-48 TMM-Corp-Site-Icons-49 TMM-Corp-Site-Icons-50 TMM-Corp-Site-Icons-51 TMM-Corp-Site-Icons-52 TMM-Corp-Site-Icons-53 TMM-Corp-Site-Icons-54 TMM-Corp-Site-Icons-55 TMM-Corp-Site-Icons-56 TMM-Corp-Site-Icons-57 TMM-Corp-Site-Icons-58 TMM-Corp-Site-Icons-59 TMM-Corp-Site-Icons-60 TMM-Corp-Site-Icons-61 TMM-Corp-Site-Icons-62 TMM-Corp-Site-Icons-63 TMM-Corp-Site-Icons-64 TMM-Corp-Site-Icons-65 TMM-Corp-Site-Icons-66 TMM-Corp-Site-Icons-67 TMM-Corp-Site-Icons-68 TMM-Corp-Site-Icons-69 TMM-Corp-Site-Icons-70 TMM-Corp-Site-Icons-71 TMM-Corp-Site-Icons-72